DTILPrecision Biosciences Inc
DTIL
Precision Biosciences Inc3,726
Mkt Cap
$186.55MVolume
43,878.0052W High
$8.8252W Low
$3.53PE Ratio
-2.04DTIL Fundamentals
Price
$7.58Prev Close
$7.23Open
$7.3550D MA
$7.00Beta
0.77Avg. Volume
222,523.12EPS (Annual)
-$3.63P/B
2.57Rev/Employee
$503,882.35$33.42
About
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
68
Frequently Asked Questions
What is Market Cap of Precision Biosciences Inc?
What is the 52-week high for Precision Biosciences Inc?
What is the 52-week low for Precision Biosciences Inc?
What is Precision Biosciences Inc stock price today?
What was Precision Biosciences Inc stock price yesterday?
What is the PE ratio of Precision Biosciences Inc?
What is the Price-to-Book ratio of Precision Biosciences Inc?
What is the 50-day moving average of Precision Biosciences Inc?
How many employees does Precision Biosciences Inc have?
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest DTIL News
ViewPrecision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Advertisement|Remove ads.